Treatment-resistant depression approaches to treatment

Karan S. Kverno, Emma Mangano

Research output: Contribution to journalArticlepeer-review

Abstract

Approximately 30% of people treated for a major depressive episode will not achieve remission after two or more treatment trials of first-line antidepressants and are considered to have treatment-resistant depression (TRD). Because the odds of remission decrease with every subsequent medication trial, it is important for clinicians to understand the characteristics and risk factors for TRD, subtypes of major depressive disorder that are more likely to be less responsive to first-line antidepressants, and the available treatment options. In the current article, we review the approved treatments for TRD, including esketamine, and the evidence for psilocybin and pramipexole. Although limited in specificity, guidelines to help prescribers identify person-centered treatments for TRD are available. [Journal of Psychosocial.

Original languageEnglish (US)
Pages (from-to)7-11
Number of pages5
JournalJournal of psychosocial nursing and mental health services
Volume59
Issue number9
DOIs
StatePublished - Sep 2021

ASJC Scopus subject areas

  • Nursing(all)
  • Phychiatric Mental Health

Fingerprint

Dive into the research topics of 'Treatment-resistant depression approaches to treatment'. Together they form a unique fingerprint.

Cite this